Non Small Cell Lung Cancer - selpercatinib + pralsetinib - RET rearrangement

Association details:

Biomarker:	RET rearrangement
Cancer:	Non Small Cell Lung Cancer
Drug:	Retevmo (selpercatinib) (RET inhibitor) + Gavreto (pralsetinib) (RET inhibitor)
Direction:	Sensitive

Evidence:

Evidence Level:

Sensitive: C3 – Early Trials

Source:

Ther Adv Med Oncol

Title:

Current management of RET rearranged non-small cell lung cancer

Published date:

07/26/2020

Excerpt:

Preliminary results from early phase trials of selpercatinib (LOXO-292) and pralsetinib (BLU-667) revealed promising efficacy and improved tolerability. The availability of these agents will make routine testing for RET rearrangements a priority.

DOI:

10.1177/1758835920928634